Enfuvirtide is an inhibitor of Human Immunodeficiency Virus fusion of susceptible cells, making the virus useless. In a more detailed mechanism of action, the drug attaches itself to the outer lining of the susceptible cell and binds with it to prevent the fusion of the virus itself from attaching to the same cell.
The marketed drug called Fuzeon or T-20 is classified as an antiviral drug created by the combined efforts of the people over at Roche and Trimeris.
Its structure is a simple linear chain of amino acids, 36 to be exact made up of synthetic peptides with terminals acetylated and carboxamide covered.
Being treated with the drug costs quite much per year as patients receiving full therapy are expected to allocate more than 20 thousand dollars per year on therapy alone. This expensive means of medication regimen has earned the drug to be called a "salvage" drug as it is given to desperately infected patients with severe cases of immunodeficiency.
The drug was first engineered at Duke University as part of the research by Trimeris. Its development was partnered by the intervention of La Roche and was therefore completed. By 2003, final approval by the FDA was given, to be used among normal medical conditions.
Enfuvirtide is a prescription drug used for those who have a significantly low level immune system. Children as early as a little over 6 months of age may be administered with the drug under strict supervision. It is practically the last resort for antiretroviral therapy, and only used after many other forms of milder regimens have failed.
The drug is administered via subcutaneous injection. In its marketed form, it originally is powdered and requires a reconstitution of sterile water to create the right formulation. There are single dose vials that may have about 108 milligrams of enfuvirtide that may be reconstituted to create a formula of 90 milligrams per milliliter. The drug is then administered twice daily, unless indicated as lowered for some special case preferences.
Common side effects associated with the administration of the enfuvirtide would be an inflammation and pain at the injection site, rashes, redness, and systemic signs and symptoms such as nausea, headaches, vomiting, and fluctuating heart rates.
There are more serious reactions such as internal bleeding, peripheral neuropathy, dyspnea, and even the more serious glomerulonephritis. In the event that these suddenly occur, it would be advisable to immediately stop the current administration if time permits, and seek the help of a physician.
It is highly suggested that the patient who is about to undergo this medication regimen inform the prescribing physician of previous and current medication as this may prove dangerous if interactions occur unexpectedly between drugs.
It is also advised that people who are about to undergo treatment with this drug should stop smoking and indicate any complications that may have manifested out of the vices and hobbies.
Pregnancy also poses a risk for the growing child, as well as the just born ones. Since there is no substantial evidence that the medicine is able to penetrate and seep through the breast milk, it is safer to assume that the HIV itself does, and should therefore be avoided nonetheless.
• Molecular formula of enfuvirtide is C202H298N50O64
• Molecular weight is 4450.8 g/mol
©2007-2017 Medicalook.com All rights reserved